Chimerix, Inc (CMRX) Net earnings per share growth forecast for next year

Corporate company logo of Chimerix, Inc. (CMRX)

Chimerix, Inc. develops anti-tumor agents while facing risks from trade barriers and logistical disruptions. The consensus EPS growth rate for the coming year visualizes these geopolitical challenges, with the current value equal to 31.90. The company is currently focusing its resources on the final stage of trials for its glioma drug. Financial stability is based on government contracts, while future success depends on regulatory approval.

Chimerix, Inc (CMRX): Net earnings per share growth forecast for next year from 07/04/2022 to 04/26/2025

Summary analytical data breakdowns for chimerix.com (CMRX)

- share price and consensus valuation forecast:
Stock Price Chimerix, Inc|CMRX - Consensus Target
- market capitalization details:
Market Value Chimerix|CMRX - Total Enterprise Value
- company book value details:
Net Assets per Single Share Chimerix|CMRX - Company Book Value|Market Value to Book Value Ratio chimerix.com|CMRX - Company Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Chimerix, Inc.|CMRX - Long-Term Indebtedness to Equity|Short-Term Debt to Equity Ratio Chimerix|CMRX - Company Cumulative Debt|Debt to Book Value Chimerix|CMRX - Company Long-Term Loans and Borrowings|Company Current Liabilities Chimerix|Quick Ratio chimerix.com
- net income and valuation ratios data:
CMRX - Final Profit|Projected Future Earnings Chimerix, Inc.|CMRX - Market Cap to Earnings|Future Price to Earnings Chimerix, Inc.|CMRX - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Chimerix|CMRX - Operating profit EBITDA|Earnings per share for the last twelve months Chimerix|CMRX - Earnings per one share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months chimerix.com|CMRX - Earnings per share growth rate in current year|Earnings growth forecast for next year Chimerix, Inc.
Fundamental company analysis:Chimerix, Inc
Finished products of Chimerix Inc.

Investors verify the issuer's financial stability by analyzing expected profit trends, which determine debt service potential. The one-year forward EPS growth trend reflects the consensus forecast for changes in net income per share, which, for a biotech company like Chimerix, Inc. (CMRX) with a minimal operational footprint and a focus on clinical development, serves as a key indicator of market confidence in drug commercialization.

Competitor analysis for Chimerix, Inc.

INCY (Incyte Corp.) - Earnings growth forecast for next year|Expected earnings per share growth for next year HUTCHMED Corp (HCM)|Net earnings per share growth forecast for next year Nuvation Bio Inc. (NUVB)|DAWN - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year Monopar Therapeutics Inc. MNPR|Inhibrx - Net earnings per share growth forecast for next year|IMAB - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Fennec|HRTX: Earnings growth forecast for next year|Net earnings per one share growth forecast for next year nuvectis.com NVCT|Expected earnings per share growth for next year CHRS|Expected net earnings per share growth next year Corbus Pharmaceuticals Holdings, Inc. CRBP|Expected earnings per share growth for next year CRDF (Cardiff Oncology, Inc.)|BYSI (BeyondSpring Inc) - Expected earnings per share trend next year|BioAtla - Expected earnings per share growth for next year|Projected earnings per share increase next year LIXT (lixte.com)|Citius Pharma - Earnings growth forecast for next year|Expected earnings per share trend next year CLRB (Cellectar Biosciences Inc)|BLRX: Earnings growth forecast for next year|Expected net earnings per share growth next year Can-Fite (CANF)|Net earnings per share growth forecast for next year Aprea Therapeutics Inc.|KZIA: Expected earnings per share trend next year|Earnings growth forecast for next year SLXN|Earnings growth forecast for next year nucana.com (NCNA)|Net earnings per share growth forecast for next year Cyclacel Pharmaceuticals Inc. CYCC|GTHX (G1 Therapeutics Inc.) - Net earnings per share change forecast for next year|KRON: Expected earnings per share growth for next year|Expected net earnings per share growth next year kintara.com|ONCT: Earnings growth forecast for next year|Expected earnings per share growth for next year Portage Biotech Inc